- Home
- ABSI vs RCKT Comparison
ABSI vs RCKT Comparison
Compare ABSI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- RCKT
- Stock Information
- Founded
- ABSI 2011
- RCKT 1999
- Country
- ABSI United States
- RCKT United States
- Employees
- ABSI N/A
- RCKT N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- RCKT Health Care
- Exchange
- ABSI Nasdaq
- RCKT Nasdaq
- Market Cap
- ABSI 338.0M
- RCKT 326.4M
- IPO Year
- ABSI 2021
- RCKT N/A
- Fundamental
- Price
- ABSI $2.79
- RCKT $2.70
- Analyst Decision
- ABSI Strong Buy
- RCKT Buy
- Analyst Count
- ABSI 5
- RCKT 13
- Target Price
- ABSI $8.40
- RCKT $18.50
- AVG Volume (30 Days)
- ABSI 2.9M
- RCKT 8.4M
- Earning Date
- ABSI 08-13-2025
- RCKT 08-04-2025
- Dividend Yield
- ABSI N/A
- RCKT N/A
- EPS Growth
- ABSI N/A
- RCKT N/A
- EPS
- ABSI N/A
- RCKT N/A
- Revenue
- ABSI $4,815,000.00
- RCKT N/A
- Revenue This Year
- ABSI $81.76
- RCKT N/A
- Revenue Next Year
- ABSI $287.79
- RCKT N/A
- P/E Ratio
- ABSI N/A
- RCKT N/A
- Revenue Growth
- ABSI N/A
- RCKT N/A
- 52 Week Low
- ABSI $2.01
- RCKT $2.19
- 52 Week High
- ABSI $6.33
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- ABSI 47.46
- RCKT 32.09
- Support Level
- ABSI $2.65
- RCKT $2.66
- Resistance Level
- ABSI $2.87
- RCKT $3.33
- Average True Range (ATR)
- ABSI 0.19
- RCKT 0.28
- MACD
- ABSI -0.01
- RCKT 0.09
- Stochastic Oscillator
- ABSI 24.03
- RCKT 26.59
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.